Published in Antiviral Res on May 27, 2015
HIV-1 Latency and Eradication: Past, Present and Future. Curr HIV Res (2016) 0.80
Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. J Clin Invest (2017) 0.77
Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary. AIDS Res Hum Retroviruses (2016) 0.77
Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. PLoS One (2015) 0.76
An enhanced Emtricitabine loaded long-acting nano-formulation for prevention or treatment of HIV infection. Antimicrob Agents Chemother (2016) 0.75
Investigational protease inhibitors as antiretroviral therapies. Expert Opin Investig Drugs (2016) 0.75
Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv (2017) 0.75
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol (2006) 2.24
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis (2012) 1.23
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine (2013) 1.21
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother (2013) 1.17
Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med (2014) 1.08
UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.05
Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp (2010) 1.03
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother (2005) 1.00
Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials (2014) 0.90
Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol (2010) 1.09
Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials (2014) 0.90